<DOC>
	<DOCNO>NCT00382720</DOCNO>
	<brief_summary>This phase II study address use docetaxel combination oxaliplatin without 5-FU capecitabine metastatic locally recurrent gastric cancer previously untreated chemotherapy advanced disease . Prior study pilot phase I ( part I ) determine optimal dose assess safety tolerability 2 dose level arm . The optimal dose administer Part II study . Participants receive optimal dose treatment arm Part I include Part II analysis population . Primary objective : - To assess time progression ( TTP ) Docetaxel combination Oxaliplatin without 5-Fluorouracil ( 5-FU ) Capecitabine metastatic locally recurrent gastric cancer previously untreated chemotherapy advanced disease ( part II ) . Secondary objective : - To establish safety profile . - To assess Overall Response Rate ( ORR ) base World Health Organization ( WHO ) criteria - To assess Overall Survival ( OS )</brief_summary>
	<brief_title>Docetaxel Oxaliplatin Gastric Cancer</brief_title>
	<detailed_description>The purpose study ( Part II ) evaluate time progression 3 arm optimal dose level docetaxel oxaliplatin define prior pilot ( Part I ) phase study . The estimated duration treatment 6 month . Treatment administered progression , unacceptable toxicity , withdrawal consent . The reason date removal participant document case report form . Participants end treatment yet progress ( e.g . unacceptable toxicity withdrawal consent ) follow every 8 week complete tumor assessment document progression anti-tumor therapy . Then , would follow every 3 month progression survival status ; date death progression report . Participants end treatment progression , follow every 3 month death . Date death report . The planned duration study 30 month .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Inclusion criterion : Histologically proven gastric adenocarcinoma , include adenocarcinoma gastrooesophageal junction Metastatic locally recurrent disease Prior adjuvant ( and/or neoadjuvant ) chemotherapy 5Fluorouracil , Cisplatin , epirubicin allow provided patient relapse &gt; 12 month end chemotherapy Performance status Karnofsky index &gt; 70 Hematology within 7 day randomization : Hemoglobin ≥10g/dl , Absolute Neutrophil Count ≥2.0 10^9/L , platelet ≥100 x 10^9/L Blood chemistry within 7 day randomization : Total bilirubin ≤1x Upper Normal Limit ( UNL ) , Aspartate Aminotransferase ( AST ) Serum Glutamic Oxaloacetic Transaminase SGOT ) Alanine Aminotransferase ( ALT ) Serum Glutamate Pyruvate Transaminase ( SGPT ) ≤2.5xUNL , alkaline phosphatase ≤ 5x UNL , provide AST ALT &gt; 1.5 x UNL associate alkaline phosphatase &gt; 2.5 x UNL ; creatinine ≤1.25x UNL 1.25x UNL &lt; creatinine ≤1.5x UNL calculated/measured creatinine clearance ≥60 ml/min ) Measurable and/or evaluable metastatic disease Exclusion criterion : Any prior palliative chemotherapy Neurosensory symptom National Cancer Institute Common Toxicity Criteria Adverse Events grade≥2 The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>